Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States

Croatian Medical Journal

Volumn 52, Issue 2, 2011, Pages 183-197

  Vogler, Sabine ^a   Habl, Claudia ^a   Bogut, Martina ^b   Vončina, Luka ^b  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b Croatian Institute of Health Insurance   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; CROATIA; DRUG EFFICACY; DRUG MARKETING; EUROPE; HEALTH CARE POLICY; HEALTH INSURANCE; PHARMACY; REIMBURSEMENT;

CROATIA; EUROPEAN UNION; INSURANCE, HEALTH, REIMBURSEMENT; ORGANIZATIONAL POLICY; PHARMACEUTICAL PREPARATIONS;

EID: 79959752316     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2011.52.183     Document Type: Article

References (73)

1. Kovacic L, Sosic Z. Organization of health care in Croatia: needs and priorities. Croat Med J. 1998;39:249-55.
2. Hebrang A, Henigsberg N, Erdeljic V, Foro S, Vidjak V, Grga A, et al. Privatization in the health care system of Croatia: effects on general practice accessibility. Health Policy Plan. 2003;18:421-8.
3. Hebrang A. Reorganization of the Croatian health care system. Croat Med J. 1994;35:130-6.
4. Mastilica M, Bozikov J. Out-of-pocket payments for health care in Croatia: implications for equity. Croat Med J. 1999;40:152-9.
5. Mastilica M. Kuec S. Croatian healthcare system in transition, from the perspective of users. BMJ. 2005;331:223-6.
6. Turek S. Reform of health insurance in Croatia. Croat Med J. 1999;40:143-51.
7. Tomic S, Filipovic Sucic A, Plazonic A, Truban Zulj R, Macolic Sarinic V, Cudina B, et al. Regulating medicines in Croatia: five-year experience of Agency for Medicinal Products and Medical Devices. Croat Med J. 2010;51:104-12.
8. E uropean Union candidate countries. Available from: http://europa.eu/abc/european_countries/candidate_countries/index_en.htm . Accessed: March 22, 2011.
9. Pignatti F, Boone H, Moulon I. Overview of the European regulatory approval system. J Ambul Care Manage. 2004;27:89-97.
10. Council Directive of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems (89/105/EEC). Available from: http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31989L0105:en :HTML. Accessed: March 22, 2011.
11. Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ. 2004;329:1169-72.
12. Hogerzeil HV, Samson M, Casanovas JV, Rahmani-Ocora L. Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts? Lancet. 2006;368:305-11.
13. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? Bull World Health Organ. 2006;84:371-5.
14. World Health Organization. The world medicines situation. Geneva (Switzerland): World Health Organization; 2004.
15. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middleincome countries: a secondary analysis. Lancet. 2009;373:240-9.
16. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability. An international comparison of chronic disease medicines. Cairo: World Health Organization, Regional Office for the Eastern Mediterranean. Health Action International; 2006.
17. WHO. Public-private roles in the pharmaceutical sector: Implications for equitable access and rational drug use. Geneva (Switzerland): World Health Organization; 1997.
18. Vogler S, Habl C, Leopold C, Rosian-Schikuta I, de Joncheere K, Lyager Thompsen T. PPRI Report. Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG; 2008.
19. OECD. Health Database 2010. Available from: http://www.oecd.org/document/30/0,3746,en_2649_33929_12968734_1_1_1_1,00 .html. Accessed: March 29, 2011.
20. Mossialos E, Mrazek M, Walley T. Regulating pharmaceuticals in Europe: striving for efficiency, equity, and quality. Maidenhead (UK): Open University Press; 2004.
21. Mrazek MF. Comparative approaches to pharmaceutical price regulation in the European Union. Croat Med J. 2002;43:453-61.
22. Mossialos E, Brogan D, Walley T. Pharmaceutical pricing in Europe: weighing up the options. Int Soc Secur Rev. 2006;59:3-25.
23. Rosian I, Antony K, Habl C, Vogler S, Weigl M. Benchmarking pharmaceuticals. Market control in nine European countries. Vienna: ÖBIG; 1998.
24. Various authors. Country Reports Pharmaceutical Pricing and reimbursement policies. London: LSE health. Pharmaceutical Pricing Board and Social Insurance Institution: 2003.
25. Various authors. PPRI Pharma Profiles. 2006/2007/2008. Available: http://ppri.oebig.at/index.aspx?Navigation=r%7C2%7C1. Accessed: March 29, 2011.
26. Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plann Manage. 2005;20:291-306.
27. Freemantle N, Behmane D, de Joncheere K. Pricing and reimbursement of pharmaceuticals in the Baltic States. Lancet. 2001;358:260.
28. Walley T, Mossialos EA, Mrazek M, de Joncheere CP. Supply and regulation of medicines. BMJ. 2005;331:171-2.
29. Kazakov R. Pricing and reimbursement policies in new EU accession countries. J Gene Med. 2007;4:249-58.
30. Vogler S, Antony K, Leopold C. Pharmaceutical Systems in the new EU Member States. Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG; 2005.
31. Habl C, Antony K, Arts D, Entleitner M, Fröschl B, Leopold C, et al. Surveying, assessing and analysing the pharmaceutical sector in the 25 member states. Vienna: ÖBIG; 2005.
32. Vogler S, Espin J, Habl C. Pharmaceutical Pricing and Reimbursement Information (PPRI) - new PPRI analysis including Spain. Pharmaceuticals Policy and Law. 2009;11:213-34.
33. Cohen J, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics. 2007;25:727-34.
34. Drummond M, Jönsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy. 1997;40:199-215.
35. Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law. 2008;33:225-47.
36. Drummond M, Jönsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ. 2010 Aug 28. [Epub ahead of print]
37. Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care: the role of health technology assessment in the European Union. London, European Observatory for Health Systems and Policies; 2008.
38. OECD. Pharmaceutical pricing policies in a global market. Paris: OECD Health Policy Studies; 2008
39. E spin J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Brussels: DG Enterprise and Industry of the European Commission; 2007.
40. Voncina L, Strizrep T. Croatia: 2009/2010 pharmaceutical pricing and reimbursement reform. Eurohealth. 2011.
41. PHIS/SOGETI/GÖG. PHIS Indicators. 2009. Available from: http://phis.goeg.at. Accessed: March 23, 2011.
42. E URO-MED STAT Group. EURO-MED-STAT: monitoring expenditure and utilization of medicinal products in the European Union countries: a public health approach. Eur J Public Health. 2003;13:95-100.
43. SOGETI. Development of public health performance indicators for the pharmaceutical sector. Final Report 2006. Available from: http://ec.europa.eu/health/ph_information/indicators/docs/final_report_h ealth_indicators_en.pdf. Accessed: March 23, 2011.
44. Arts D, Habl C, Rosian I, Vogler S. Pharmaceutical Pricing and Reimbursement Information (PPRI): a European Union project. Italian Journal of Public Health. 2006;3:36-40.
45. Morak S. Pharmaceutical system Croatia. Factsheet [in German]. Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG; 2009.
46. Legal basis for PPI: General Social Insurance Act § 351c, Federal Law No. 189/1955, latest change by Federal Law No. I No. 33/2009 [in German]. Available from: http://www.ris.bka.gv.at/Dokument.wxe?Abfrage=Bundesnormen&Dokumentn ummer=NOR40105284 &ResultFunctionToken=0a7387e1-130c-414d-9940-803eb8b27373 &Position=401&Kundmachungsorgan=&Index=&Titel=&Geset zesn ummer=&VonArtikel=&BisArtikel=&VonParagraf=&BisParagraf= &V onAnlage=&BisAnlage=&Typ=&Kundmachungsnummer=&Unterz eichnungsdatum=&FassungVom=28.03.2011&Normabschnittnum merKombination=Und&ImRisSeit=Undefined&ResultPageSize=10 0&Suchworte=Allgemeines+Sozialversicherungsgesetz. Accessed: March 29, 2011.
47. Pharma-Preisinformation. Available from: http://www.goeg.at/en/PPI. Accessed: March 23, 2011.
48. PHIS/AIFA/GÖG. PHIS Glossary: Glossary for pharmaceutical policies/systems developed in the Pharmaceutical Health Information System (PHIS) Project. 2009. Available from: http://phis.goeg.at/index.aspx?_nav0020. Accessed: March 23, 2011.
49. Leopold C, Habl C, Rosian-Schikuta I. Control of pharmaceutical consumption - the example of Denmark [in German]. Vienna: Gesundheit Österreich / Geschäftsbereich ÖBIG; 2008.
50. Glaeske G, Klauber J, Lankers C, Selke G. Reinforcing competitiveness in the pharmaceutical provision for the sake of the consumers, efficiency and quality [in German]. Berlin: WidO; 2003.
51. Vogler S, Habl C, Leopold C. Pharmaceuticals: who pays? Reimbursement and co-payments in the enlarged EU [in German]. Soziale Sicherheit. 2006;9:411-8.
52. Puig-Junoy J. Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics. 2010;28:649-63.
53. Vogler S. Pharmaceutical pricing and reimbursement in the EU [in German]. Austrian Public Health Association Newsletter. 2008;4:1-2.
54. DeSwaef A, Antonissen Y, Pharma Profile Belgium PPRI. Brussels: PPRI; 2008. Available from: http://ppri.oebig.at/Downloads/Results/Belgium_PPRI_2008.pdf. Accessed: March 29, 2011.
55. Teixeira I, Agostinho I. PPRI Pharma Profile Portugal. Lisbon: PPRI; 2008. Available from: http://ppri.oebig.at/Downloads/Results/Portugal_PPRI_2008.pdf. Accessed: March 29, 2011.
56. Vogler S, Leopold C. Access to essential medicines in Portugal. Vienna: ÖBIG Forschungs- und Planungsgesellschaft mbH; 2009.
57. Simoens S, Coster S. Sustaining generics medicines markets in Europe. Leuven (Belgium): Research Centre for Pharmaceutical Care and Pharmaco-economics. Leuven University; 2006.
58. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Gene Med. 2006;3:257-68.
59. Habl C, Vogler S, Leopold C, Schmickl B, Fröschl B. Reference price systems in Europe. Analysis and prequisites for an implementation in Austria [in German]. Vienna: ÖBIG Forschungs- und Planungsgesellschaft mbH; 2008.
60. Weigl M, Antony K. Pharmaceutical Systems in Bulgaria and Romania [in German]. Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG; 2008.
61. Vogler S, Habl C, Leopold C. PPRI at a Glance. Vienna: Gesundheit Österreich / Geschäftsbereich ÖBIG; 2008.
62. Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N. PHIS Hospital Pharma Report. Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG, State Institute for Drug Control SUKL; 2010.
63. Danzon PM, Kim JD. International price comparisons for pharmaceuticals. Measurement and policy issues. Pharmacoeconomics. 1998;14 Suppl 1:115-28.
64. Danzon PM, Chao LW. Cross-national price differences for pharmaceuticals: how large, and why? J Health Econ. 2000;19:159-95.
65. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs-evidence from twentyfive major markets in the 1990s. Health Econ. 2005;14:269-92.
66. Sood N, de Vries H, Gutierrez I, Lakdawalla DN, Goldman DP. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Aff (Millwood). 2009;28:w125-37.
67. Leopold C, Vogler S, Habl C. Implementing a successful reference price system - Experiences from other countries [in German]. Soziale Sicherheit. 2008;11:614-23.
68. Simoens S. Generic medicine pricing in Europe: current issues and future perspective. J Med Econ. 2008;11:171-5.
69. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002;43:462-9.
70. Simoens S. Developing competitive and sustainable Polish generic medicines market. Croat Med J. 2009;50:440-8.
71. Harvey K, Kalanj K, Stevanović R. Croatian pharmaceutical sector reform project: rational drug use. Croat Med J. 2004;45:611-9.
72. Lamza-Maronić M, Glavaš J. Pharmaceutical market in the Republic of Croatia. Med Glas. 2008;5:44-38.
73. PPRI. GÖG, WHO. Set of PPRI Indicators. Vienna: Gesundheit Österreich / Geschäftsbereich ÖBIG; 2008.